BRCA2 and malignant mesothelioma: Because of the promising results of PARPi therapy in BRCA (germline) mutated malignant mesotheliomas, the considerable frequency of BRCA2 somatic variants in malignant mesotheliomas found in this study and the putative effect of these variants on protein properties including intrinsic disorder, these findings merit further evaluation in a larger cohort.